PMID- 37312528
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR  - 20231216
IS  - 1724-6008 (Electronic)
IS  - 0393-6155 (Linking)
VI  - 38
IP  - 3-4
DP  - 2023 Dec
TI  - NRF2/HO-1 axis, BIRC5, and TP53 expression in ESCC and its correlation with 
      clinical pathological characteristics and prognosis.
PG  - 174-184
LID - 10.1177/03936155231176571 [doi]
AB  - BACKGROUND: Many types of cancer exhibit high nuclear factor erythroid 2-related 
      factor 2 (NRF2), which is effective in resisting drugs and radiation. However, 
      the role of NRF2 gene expression in predicting the prognosis of esophageal 
      squamous cell carcinoma (ESCC) remains unclear. METHODS: The association between 
      NRF2, heme oxygenase-1 (HO-1), baculovirus IAP repeat 5 (BIRC5), P53 gene 
      expression levels and their relationship to immune-infiltrating cells were 
      assessed using the Cancer Genome Atlas dataset, the Human Protein Atlas and the 
      TISDB database. The expression of NRF2, HO-1, BIRC5, and TP53 in 118 ESCC 
      patients was detected by immunohistochemistry, and the relationship between their 
      expression level and clinicopathological parameters and prognosis was analyzed. 
      RESULTS: In ESCC, NRF2 overexpression was significantly associated with Han 
      ethnicity, lymph node metastasis, and distant metastasis. HO-1 overexpression was 
      significantly associated with differentiation, advanced clinical staging, lymph 
      node metastasis, nerve invasion, and distant metastasis. BIRC5 overexpression was 
      significantly associated with Han ethnicity and lymph node metastasis. TP53 
      overexpression was significantly associated with Han ethnicity and T staging. The 
      NRF2/HO-1 axis expression was positively correlated with BIRC5 and TP53. 
      Kaplan-Meier and multivariate Cox regression analysis showed that NRF2, BIRC5, 
      and TP53 genes co-expression was an independent prognostic risk factor. TISIDB 
      dataset analysis showed that immune-infiltrating cells were significantly 
      negatively correlated with NRF2 and BIRC5. CONCLUSION: NRF2, BIRC5, and TP53 axis 
      gene expressions are predictors of poor prognosis for ESCC. The overexpression of 
      the NRF2/HO-1/BIRC5 axis may not be related to immune-infiltrating cells.
FAU - Gao, Yongmei
AU  - Gao Y
AD  - Department of Pathology, The First Affiliated Hospital of Xinjiang Medical 
      University, Urumqi, China. RINGGOLD: 159427
FAU - Wan, Li
AU  - Wan L
AD  - Department of Pathology, The First Affiliated Hospital of Xinjiang Medical 
      University, Urumqi, China. RINGGOLD: 159427
FAU - Li, Mengyan
AU  - Li M
AD  - Department of Pathology, The First Affiliated Hospital of Xinjiang Medical 
      University, Urumqi, China. RINGGOLD: 159427
FAU - Wang, Bo
AU  - Wang B
AD  - Department of Pathology, The First Affiliated Hospital of Xinjiang Medical 
      University, Urumqi, China. RINGGOLD: 159427
FAU - Ma, Yuqing
AU  - Ma Y
AUID- ORCID: 0000-0001-8009-4358
AD  - Department of Pathology, The First Affiliated Hospital of Xinjiang Medical 
      University, Urumqi, China. RINGGOLD: 159427
LA  - eng
PT  - Journal Article
DEP - 20230614
PL  - United States
TA  - Int J Biol Markers
JT  - The International journal of biological markers
JID - 8712411
RN  - 0 (NF-E2-Related Factor 2)
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Survivin)
SB  - IM
MH  - Humans
MH  - *Esophageal Squamous Cell Carcinoma/genetics
MH  - *Carcinoma, Squamous Cell/pathology
MH  - NF-E2-Related Factor 2/genetics/metabolism
MH  - *Esophageal Neoplasms/pathology
MH  - Lymphatic Metastasis
MH  - Heme Oxygenase-1/genetics/metabolism
MH  - Baculoviridae/metabolism
MH  - Prognosis
MH  - Biomarkers, Tumor/metabolism
MH  - Tumor Suppressor Protein p53/genetics
MH  - Survivin/genetics/metabolism
OTO - NOTNLM
OT  - BIRC5
OT  - NRF2
OT  - co-expression
OT  - esophageal squamous cell carcinoma
OT  - lymph node metastasis
OT  - prognosis
COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2023/06/14 06:42
MHDA- 2023/12/17 09:44
CRDT- 2023/06/14 03:38
PHST- 2023/12/17 09:44 [medline]
PHST- 2023/06/14 06:42 [pubmed]
PHST- 2023/06/14 03:38 [entrez]
AID - 10.1177/03936155231176571 [doi]
PST - ppublish
SO  - Int J Biol Markers. 2023 Dec;38(3-4):174-184. doi: 10.1177/03936155231176571. 
      Epub 2023 Jun 14.